Steven Carl Quay
Physician in Seattle, WA
License number
Utah 8177459-1205
Issued Date
Apr 2, 2012
Expiration Date
Jan 31, 2016
Category
Physician
Type
Physician & Surgeon
Address
Address
Seattle, WA
Education
UNIVERSITY OF MICHIGAN MEDICAL SCHOOL
Personal information
See more information about Steven Carl Quay at radaris.comName
Address
Phone
3916 E Pine St, Seattle, WA 98122
2998 232Nd St, Brier, WA 98036
23632 Highway 99, Edmonds, WA 98026
22829 Woodway Park Rd, Edmonds, WA 98020
3916 Pine St, Seattle, WA 98122
Professional information
Ceo, Atossa Genetics, Inc.
Location:
Greater Seattle Area
Industry:
Biotechnology
Steven Carl Quay, Seattle WA
Specialties:
Pathologist
Address:
1124 Columbia St, Seattle, WA 98104
Intranasal Carbetocin Formulations And Methods For The Treatment Of Autism
US Patent:
2012017, Jul 5, 2012
Filed:
Aug 5, 2011
Appl. No.:
13/204485
Inventors:
Alexis Kays LEONARD - Maple Valley WA, US
Joshua Orion SESTAK - Lawrence KS, US
Henry R. COSTANTINO - Woodinville WA, US
Anthony P. SILENO - Mendham NY, US
Lalit Raj PEDDAKOTA - San Diego CA, US
Kayvon Emile SHARGHI - Chevy Chase MD, US
Garland M. BELLAMY - Santa Fee NM, US
Jason Philip GESTY - Seattle WA, US
Steven C. QUAY - Seattle WA, US
Joshua Orion SESTAK - Lawrence KS, US
Henry R. COSTANTINO - Woodinville WA, US
Anthony P. SILENO - Mendham NY, US
Lalit Raj PEDDAKOTA - San Diego CA, US
Kayvon Emile SHARGHI - Chevy Chase MD, US
Garland M. BELLAMY - Santa Fee NM, US
Jason Philip GESTY - Seattle WA, US
Steven C. QUAY - Seattle WA, US
International Classification:
A61K 38/11, A61P 25/28, A61P 25/24, A61P 25/00, A61P 25/22
US Classification:
514 116
Abstract:
Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.
Intranasal Formulations Of Interferon Beta Free Of Stabilizers That Are Proteins Or Polypeptides
US Patent:
2007021, Sep 13, 2007
Filed:
Jun 7, 2005
Appl. No.:
11/570068
Inventors:
Steven Quay - Seattle WA, US
Henry Costantino - Woodinville WA, US
Henry Costantino - Woodinville WA, US
International Classification:
A61K 9/12, A61K 38/21
US Classification:
424045000, 424085500
Abstract:
Compositions and methods are provided for intranasal delivery of interferon-β yielding improved pharmacokinetic and pharmacodynamic results wherein the composition is free of a stabilizer that is a protein or a polypeptide. In certain aspects of the invention, the interferon-β is delivered to the intranasal mucosa along with one or more intranasal delivery-enhancing agent(s) to yield substantially increased absorption and/or bioavailability of the interferon-β and/or a substantially decreased time to maximal concentration of interferon-β in a tissue of a subject as compared to controls where the interferon-β is administered to the same intranasal site alone or formulated according to previously disclosed reports. The enhancement of intranasal delivery of interferon-β according to the methods and compositions of the present invention allows for the effective pharmaceutical use of these agents to treat a variety of diseases and conditions in mammalian subjects.
Compositions And Methods For The Treatment Of Psychiatric Disorders
US Patent:
2007003, Feb 8, 2007
Filed:
Sep 29, 2006
Appl. No.:
11/537468
Inventors:
Steven Quay - Seattle WA, US
Alexis Leonard - Maple Valley WA, US
Henry Costantino - Woodinville WA, US
Anthony Sileno - Brookhaven Hamlet NY, US
Joshua Sestak - Kirkland WA, US
Alexis Leonard - Maple Valley WA, US
Henry Costantino - Woodinville WA, US
Anthony Sileno - Brookhaven Hamlet NY, US
Joshua Sestak - Kirkland WA, US
International Classification:
A61K 38/22
US Classification:
514009000, 514012000
Abstract:
Methods and compositions containing oxytocin or an oxytocin analog, specifically carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of the invention are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.
Method Of Treating Osteoporosis Using Intranasal Parathyroid Hormone
US Patent:
2006005, Mar 9, 2006
Filed:
Oct 6, 2005
Appl. No.:
11/246406
Inventors:
Steven Quay - Seattle WA, US
Gordon Brandt - Issaquah WA, US
Henry Costantino - Woodinville WA, US
Gordon Brandt - Issaquah WA, US
Henry Costantino - Woodinville WA, US
International Classification:
A61K 38/29, A61K 31/195
US Classification:
514012000, 514566000
Abstract:
What is described is a method for treating osteoporosis in a mammal comprising administering intranasally a therapeutically effective amount of a PTH formulation to the mammal wherein the PTH formulation is an aqueous formulation comprised of a PTH peptide and one or more excipients selected from the group consisting of a water-miscible polar organic solvent, a surface active agent, and a chelating agent for cations.
Method Of Enhancing Transmucosal Delivery Of Therapeutic Compounds
US Patent:
2007007, Apr 5, 2007
Filed:
Sep 29, 2006
Appl. No.:
11/536937
Inventors:
Steven Quay - Seattle WA, US
Shu-Chih Quay - Seattle WA, US
Najib Lamharzi - Bothell WA, US
Kristine Fry - Seattle WA, US
Shu-Chih Quay - Seattle WA, US
Najib Lamharzi - Bothell WA, US
Kristine Fry - Seattle WA, US
International Classification:
A61K 38/21, A61K 38/28, A61K 38/22, A61F 13/02
US Classification:
424448000, 514012000, 514003000, 514009000, 424085600, 424085500, 424085700
Abstract:
A composition comprising a biologically active agent and a permeation enhancing lipid wherein the permeation enhancing lipid is a platelet activating factor antagonist or a biologically inactive a platelet activating factor, and increases permeability of the biologically active agent across a tissue layer. Also disclosed is a process of increasing the permeability of a biological agent across a layer tissue comprising contacting the tissue layer with a composition comprising the biological agent and a permeation enhancing lipid wherein the permeation enhancing lipid is a platelet activating factor antagonist or a biologically inactive platelet activating factor.
Nucleic Acid Molecules And Uses Thereof
US Patent:
2012014, Jun 14, 2012
Filed:
Aug 27, 2010
Appl. No.:
13/392042
Inventors:
Steven C. Quay - Seattle WA, US
Assignee:
Atossa Genetics, Inc. - Seattle WA
International Classification:
A61K 31/713, A61P 35/00
US Classification:
514 44 A
Abstract:
Provided in this application are formulations of double stranded RNA molecules and Krebs Cycle analogs that improving ribonuclease stability, reducing off-target effects of a double stranded siRNA molecule, or of reducing interferon responsiveness of a double stranded siRNA molecule using such dsRNA. Also disclosed are methods of treating a primary tumor or a metastasis by contacting circulating tumor cells, a primary tumor, or a metastasis with a described formulation.
Nucleic Acid Compounds For Inhibiting Birc5 Gene Expression And Uses Thereof
US Patent:
2011023, Sep 29, 2011
Filed:
Aug 5, 2009
Appl. No.:
13/057741
Inventors:
Steven C. Quay - Seattle WA, US
James McSwiggen - Boulder CO, US
Narendra K. Vaish - Kirkland WA, US
Kathy L. Fosnaugh - Bellevue WA, US
Shaguna Seth - Bothell WA, US
James McSwiggen - Boulder CO, US
Narendra K. Vaish - Kirkland WA, US
Kathy L. Fosnaugh - Bellevue WA, US
Shaguna Seth - Bothell WA, US
Assignee:
MARINA BIOTECH, INC. - Bothell WA
International Classification:
C12N 5/071, C07H 21/02
US Classification:
435366, 536 245, 435375
Abstract:
The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), capable of decreasing or silencing BIRC5 gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a BIRC5 mRNA. Also provided are methods of decreasing expression of a BIRC5 gene in a cell or in a subject to treat a BIRC5-related disease.
Nucleic Acid Compounds For Inhibiting Gene Expression And Uses Thereof
US Patent:
2010010, Apr 29, 2010
Filed:
Sep 1, 2009
Appl. No.:
12/552082
Inventors:
Steven C. Quay - Seattle WA, US
James McSwiggen - Boulder CO, US
Narendra K. Vaish - Kirkland WA, US
Mohammad Ahmadian - Carlsbad CA, US
James McSwiggen - Boulder CO, US
Narendra K. Vaish - Kirkland WA, US
Mohammad Ahmadian - Carlsbad CA, US
Assignee:
MDRNA, Inc. - Bothell WA
International Classification:
C12N 5/071, C07H 21/02, C12N 5/00
US Classification:
435366, 536 231, 435375
Abstract:
The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), and blunt ended double-stranded ribonucleic acid molecules capable of decreasing or silencing expression of a target gene. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target mRNA. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease or condition associated with the target gene.